Nirogaya Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 02-12-2024
- Paid Up Capital ₹ 0.10 M
as on 02-12-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
About Nirogaya Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Navneet Kapoor and Asheesh Kapoor serve as directors at the Company.
- CIN/LLPIN
U24232PB2014PTC038279
- Company No.
038279
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jan 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Jalandhar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Nirogaya Pharmaceuticals Private Limited offer?
Nirogaya Pharmaceuticals Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic,Herbal Drops & Concentrates, Common Disease Medicines, Herbal Cough Syrup, Ayurvedic & Herbal Health Supplement, Herbal Juice.
Who are the key members and board of directors at Nirogaya Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Asheesh Kapoor  | Managing Director | 10-Jan-2014 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Navneet Kapoor | Director | 04-Jun-2014 | Current |
Financial Performance of Nirogaya Pharmaceuticals.
Nirogaya Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nirogaya Pharmaceuticals?
In 2017, Nirogaya Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hakim Tilak Raj Kapoor Hospital Private LimitedActive 14 years 10 monthsNavneet Kapoor and Asheesh Kapoor are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nirogaya Pharmaceuticals?
Unlock and access historical data on people associated with Nirogaya Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nirogaya Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nirogaya Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
